Sign In
Buy VNRX
$2.08
-0.240 (-10.34%)
At Close: Jun 03, 2026
New Data Demonstrates Nu.Q® is Effective in Monitoring Treatment of Sepsis
08:00am, Wednesday, 17'th Mar 2021
AUSTIN, Texas, March 17, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to
VolitionRx Limited Schedules Full Fiscal Year 2020 Earnings Conference Call and Business Update
08:30am, Tuesday, 16'th Mar 2021
AUSTIN, Texas, March 16, 2021 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced it will host a conference call on Tuesday, March 23, at 8:00 a.m. Eastern time to d
Volition Has Released A Screening Test To Help Detect Early Stages Of Cancer In Dogs
09:30am, Friday, 04'th Dec 2020
Volition is one of the sponsors for the upcoming Benzinga Global Small Cap Conference set to take place on December 8-9, 2020. Given the growing population, it is expected that the number of cancer di
VolitionRx Enters Commercial Stage
09:20am, Wednesday, 02'nd Dec 2020
VolitionRx began commercial sales of a blood test for pet cancer. There is no other product available on the market for testing cancer in dogs despite cancer being the leading cause of death for dogs
